Inflammatory Bowel Disease | CHOP Research Institute
 

Inflammatory Bowel Disease

Risankizumab is a medication used for the treatment of Crohn's Disease in adults and children to limit symptoms of the disease.

The Center for Microbial Medicine at Children’s Hospital of Philadelphia leverages the microbiome to improve the health of children and bring personalized microbiome-based medicine from bench to bedside to every child who receives care at CHOP.

Published on
Aug 14, 2023
By studying lab-grown organoids derived from patients’ stem cells, the Hamilton Lab seeks to better understand and treat IBD.

Evaluate the impact of non-persistent and persistent chemical exposures on autoimmunity, gene expression and the microbiome in children with and without Crohn’s disease.

Published on
Sep 21, 2022
A high school student in the lab of Dr. Kathryn Hamilton won two science fair awards for research he conducted at CHOP.

Dr. Mattei is an attending physician in the Division of General, Thoracic and Fetal Surgery and specializes in pediatric surgical oncology, inflammatory bowel disease, and minimally invasive and robotic surgery. His research interests are in oncology and IBD.

E-mail:
mattei [at] chop.edu

The Penn Human Intervention Core offers a wide array of services to assist with the design and implementation of microbiome studies.

The Penn Microbial Culture and Metabolomics Core features facilities and equipment for the aerobic and anaerobic culture of microbial species in both batch and continuous systems, as well targeted metabolomics services.

The Penn High-throughput Screening (PHTS) Core provides the PennCHOP research community with professional PHTS screening services to identify genes or organic small molecule modulators of signaling pathways, cellular phenotypes, and protein function in models of human disease.

The goals of the Penn Acute Care Biobanking Core are to encourage and facilitate microbiome-focused research in the pathogenesis, diagnosis, and treatment of patients with critical illness.